Correspondence on population health surveys and screening tools for depressive disorders: aims and uses by Arias de la Torre et al

Felix Fischer 1, Dario Zocholl 2, Geraldine Rauch 2, Brooke Levis 3,4, Andrea Benedetti 4,5,6, Brett Thombs 3,4,6,7,8,9, Matthias Rose 1,10, Polychronis Kostoulas 11

Arias de la Torre et al argue in ‘Population health surveys and screening tools for depressive disorders: aims and uses’ that population-based studies like the European Health Interview Survey (EHIS) are primarily intended to identify and compare vulnerable groups and factors associated with depression on a population level, not to estimate prevalence of major depressive disorders (MDD). 1 We fully agree that the use of brief depression questionnaires in such studies provides meaningful data on the perceived burden by depressive symptoms.

While questionnaire sum scores can be easily analysed, reported and compared, the common practice of reporting the share of participants that score above a given threshold as prevalence is highly problematic. For their widely cited prevalence analysis, 3 Arias de la Torre et al argue that they employed a broad definition of ‘current depressive disorders’, including MDD, dysthymia and mere occurrence of depressive symptoms or ‘probable cases of depression’. However, there is no evidence that a cut-off of 10 for the eight-item Patient Health Questionnaire depression scale (PHQ-8) accurately distinguishes persons fulfilling these vague definitions from those who do not. On the contrary, at a true prevalence of 5%, over 75% of persons with a score above the cut-off may be false positive screens (http://www.depressionscreening100.com/phq-8/). 4

When using different evaluation tools, prevalence estimates can only be compared meaningfully when the imperfect accuracy of each tool in the context of an accepted illness definition is taken into account. Analysis of depression screening tool data in a Bayesian framework enables us to derive meaningful and comparable MDD prevalence estimates from the EHIS. We have demonstrated, under a range of realistic assumptions, how little information the EHIS data actually contain about MDD prevalence, despite the large sample size. 5

The imprecision of our estimates and lack of power to establish MDD prevalence differences across countries should be understood as a consequence of the PHQ-8’s imperfect diagnostic accuracy, not as evidence for absence of such differences. Revealing this uncertainty is not a weakness but rather a strength of the Bayesian approach.

We are concerned that exaggerations of depression prevalence and the precision of estimates due to ignoring imperfect diagnostic accuracy are misleading and harmful. They potentially identify non-existent and magnify negligible prevalence differences and could therefore lead to miscalculated research and public health initiatives. The proportion of persons scoring above a cut-off on a screening test should not be reported as prevalence without appropriate adjustment for diagnostic accuracy.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement No data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Felix Fischer http://orcid.org/0000-0002-9693-6676

1 Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. felix.fischer@charite.de
2 Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
3 Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
4 Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
5 Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montreal, Quebec, Canada
6 Department of Medicine, McGill University, Montreal, Quebec, Canada
7 Department of Psychiatry, McGill University, Montreal, Quebec, Canada
8 McGill Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada
9 Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, USA
10 Faculty of Public Health, University of Thessaly, Karditsa, Greece
REFERENCES


